Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

FDA Approves Amgen’s Infliximab Biosimilar Treatment

Reuters Staff  |  December 10, 2019

(Reuters)—The U.S. Food and Drug Administration on Friday approved Amgen Inc.’s biosimilar copy of Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade (infliximab), according to the regulator’s website. The biosimilar, Avsola (infliximab-axxq), has the same chemical components, dosage form and strength as Remicade and would treat a range of autoimmune disorders. The label for the…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Avsolainfliximabinfliximab biosimilarinfliximab-axxqRemicadeREMICADE (infliximab)U.S. Food and Drug Administration (FDA)

Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA

Michele B. Kaufman, PharmD, BCGP  |  November 25, 2019

Rituximab-abbs, which is biosimilar to rituximab, is now available in the U.S. to treat specific cancers…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Cancernon-Hodgkin’s lymphomaPsoriatic Arthritisrituximabrituximab-abbsupadacitinib

A Rash of Evidence: Evaluating & Treating Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  November 20, 2019

ATLANTA—As many rheumatologists will recall, it was not too long ago that psoriatic arthritis was regarded somewhat like “rheumatoid arthritis with a rash,” with little attention paid to the ways in which the unique pathophysiology and manifestations of this entity make it distinct from other forms of inflammatory arthritis. At the 2019 ACR/ARP Annual Meeting…

Filed under:ConditionsPsoriatic Arthritis Tagged with:2019 ACR/ARP Annual MeetingPsoriatic Arthritis

Year in Review: Rheumatic Disease Research in 2019

Thomas R. Collins  |  November 20, 2019

ATLANTA—Encouraging data on interleukin (IL) 23/IL-17 pathway drugs in psoriatic arthritis (PsA), JAK inhibitors in rheumatoid arthritis (RA) treatment and new evidence on physical activity and bone health in women were among the highlights of the 2019 ACR/ARP Annual Meeting’s Clinical Year in Review. Susan Manzi, MD, MPH, director of the Lupus Center for Excellence…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:2019 ACR/ARP Annual MeetingFracturesJAK inhibitorsKnee Osteoarthritis (OA)physical activityPsoriatic ArthritisResearch

Figures 1 & 2: Transverse and longitudinal ultrasound views, respectively, of the left posterior knee, revealing a cystic mass with heterogeneous internal echotexture and no stalk.

Ultrasound Aids Diagnosis of Man with Knee Pain & Swelling

Mark H. Greenberg, MD, RMSK, RhMSUS, Prem Patel, Elijah Mitcham, MD, James W. Fant Jr., MD, & Frank R. Voss, MD  |  November 17, 2019

A 56-year-old automobile mechanic was referred to our rheumatology service by his orthopedist to evaluate left posterior knee pain and swelling that had been present for three months. The patient had undergone bilateral total knee arthroplasties (TKAs) for sports-related osteo­arthritis three years before. In addition to the knee pain, the patient described several years of…

Filed under:ConditionsRheumatoid Arthritis Tagged with:knee arthroplastyknee swellingpopliteal cystsynovitis

Scottish Medicines Consortium Recommends Risankizumab; Plus Real-World Data on Secukinumab

Michele B. Kaufman, PharmD, BCGP  |  November 4, 2019

The Scottish Medicines Consortium has released a detailed advice document recommending risankizumab for treating adults with psoriasis…

Filed under:Drug Updates Tagged with:PsoriasisrisankizumabScottish Medicines Consortiumsecukinumab

Case Report: A Patient on Apremilast Develops Streptococcus Salivarius

Stephanie Kydd Dondero, DO, & Barry Waters, MD  |  October 18, 2019

Apremilast was first marketed in March 2014 for the treatment of adults with psoriatic arthritis (PsA). An immuno­modulating drug, which is a small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine mono­phosphate (cAMP), apremilast is administered orally. By inhibiting PDE4, intracellular cAMP levels are increased. Although the exact mechanism of action is not…

Filed under:Conditions Tagged with:apremilastcase reportimmunosuppressive drugsStreptococcus salivarius

‘Cookbook Medicine’ Is More Popular Than Ever (& That’s a Good Thing)

Paula Marchetta, MD, MBA  |  October 18, 2019

In 2004, the British Medical Journal published an article titled, “Resisting Cookbook Medicine,” which looked askance at the “routine use of pre­determined directives” in clinical practice because it reduced doctors to practicing so-called cookbook medicine and eroded the art of medicine.1 Fast forward 15 years, and we find our appetite for “predetermined directives”—what we now…

Filed under:President's Perspective Tagged with:cookbook medicineDevelopment and Evaluation (GRADE)evidence-based guidelinesGrading of RecommendationsGuidelines

Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

Mary Choy, PharmD, BCGP, FASHP  |  October 14, 2019

Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:GoutGout Resource Center

Imagining a Life Free from the Pain of Ankylosing Spondylitis

Lara C. Pullen, PhD  |  September 30, 2019

Dan Reynolds, the lead singer of the Grammy award-winning band Imagine Dragons, has partnered with Novartis to increase awareness of ankylosing spondylitis.

Filed under:Axial SpondyloarthritisConditionsPsoriatic Arthritis Tagged with:Ankylosing SpondylitisMonster Pain in the ASNovartisplaque psoriasisPsoriatic Arthritissecukinumab

  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences